# The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)

> **NCT03159884** · PHASE4 · UNKNOWN · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Polypoidal Choroidal Vasculopathy (PCV)

## Interventions

- **DRUG:** Conbercept

## Key facts

- **NCT ID:** NCT03159884
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2018-06
- **Final completion:** 2018-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03159884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03159884, "The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03159884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*